Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Drug Promotion: Potential Enforcement Worries

Executive Summary

Pitfalls of using third-party hubs for reimbursement assistance, sharing preapproval data with patient groups, and promoting biosimilars with labeling carveouts are among the concerns noted by panelists at FDLI conference.

You may also be interested in...



Generic ‘Skinny Labels’ Get Reprieve As Court Agrees To Rehear Teva/GSK Case

Federal Circuit panel to reconsider whether Teva induced infringement of GSK Coreg patent despite label carve-out. Biologics and biosimilars could be particularly hurt if ruling stands given FDA’s recent guidance requiring reference to branded product.

False Claims Act: US Justice Department Gives Pharma Early Christmas Present

Government seeks dismissal of 10 qui tam complaints related to pharma reimbursement support services, asserting the lawsuits were brought by a ‘professional’ whistleblower and lack merit.

Insys ‘Reimbursement Unit’ Fraudulently Boosted Fentanyl Rxs, DOJ Charges

Six former Insys executives and managers arrested on changes of misleading insurers and pharmacy benefit managers into authorizing payments for Subsys sublingual fentanyl pain medicine.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel